2009 Form 990-PF - Bill & Melinda Gates Foundation

BILL & MELINDA GATES FOUNDATION 56-2618866
FORM 990PF, PART XV - CONTRIBUTIONS APPROVED FOR FUTURE PAYMENT
RELATIONSHIP TO SUBSTANTIAL CONTRIBUTOR
AND
ATTACHMENT 19 (CONT'D)
RECIPIENT NAME AND ADDRESS FOUNDATION STATUS OF RECIPIENT PURPOSE OF GRANT OR CONTRIBUTION AMOUNT
MARY WALKER SCHOOL DISTRICT NO 207 NONE TO SUPPORT DISTRICTS IN THEIR EFFORTS TO
214,568.
PO BOX 159 170(C)(1)
SPRINGDALE, WA 99173
IMPROVE SCHOOL READINESS
MASSACHUSETTS INST OF TECHNOLOGY NONE TO DEVELOP AND RIGOROUSLY TEST PROGRAMS THAT
3,976,074.
238 MAIN STREET 509(A)(1)
SUITE 200
CAMBRIDGE, MA 021421012
IMPROVE ADOPTION AND PROFITABLE USE OF
AGRICULTURAL TECHNOLOGY BY SMALL-SCALE FARMERS
IN SUB-SAHARAN AFRICA AND SOUTH ASIA
MASSACHUSETTS INST OF TECHNOLOGY NONE TO IMPROVE THE CHEMISTRY OF NITROGEN CATALYSTS
266,330.
238 MAIN STREET 509(A)(1)
CAMBRIDGE, MA 021421012
MATHEMATICA POLICY RESEARCH NONE TO PROVIDE RICH DATA THAT IMPROVES INSTRUCTION
228,361.
PO BOX 2393 US NON-EXEMPT
PRINCETON, NJ 085432393
AT THE EQUITY PROJECT (TEP) SUCH AS RIGOROUS
EVALUATION FINDINGS THAT DOCUMENT TEP'S IMPACT
ON STUDENTS AND EVIDENCE THAT CAN INFORM
EDUCATORS AND POLICYMAKERS WHO WISH TO
REPLICATE THE TEP MODEL
MATRIVAX INC NONE KEVIN KILLEEN OF MATRIVAX R&D INC. IN THE U.S.
100,000.
650 ALBANY STREET US NON-EXEMPT
SUITE 117
BOSTON, MA 02118
PROPOSES APPLYING A NOVEL TECHNOLOGY WHICH
ENTRAPS MANY POLYSACCHARIDE ANTIGENS IN A
PROTEIN MATRIX. IF SUCCESSFUL, THIS PROTOTYPE
PLATFORM COULD INCREASE THE BREADTH OF
SEROTYPES CURRENTLY COVERED BY PNEUMOCOCCAL
VACCINES AS WELL AS REDUCE COSTS OF VACCINE
PRODUCTION.
MAX PLANCK SOCIETY NONE TO IDENTIFY MOLECULAR AND IMMUNE RESPONSES OF
1,306,038.
CHARITEPLATZ 1 10117
FOR PUBLIC DISCLOSURE
40 OF 82
PATHOGENS AND PATIENTS WHICH CORRELATE WITH
PROTECTION FROM TB
ATTACHMENT 19